Health Canada has approved INVOKANA®* (canagliflozin) for reduction of major adverse cardiovascular events (MACE), the first SGLT2 inhibitor in Canada to receive this indication(1)

1

INVOKANA^® Product Monograph, October 15, 2018.

2

INVOKANA^® Product Monograph, October 15, 2018.

3

INVOKANA^® Product Monograph, October 15, 2018.

4

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

5

INVOKANA^® Product Monograph, October 15, 2018.

6

INVOKANA^® Product Monograph, October 15, 2018.

7

INVOKANA^® Product Monograph, October 15, 2018.

8

Diabetes Canada. 2018 National Backgrounder. Available at: http://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx. Accessed August 29, 2018.     

9

Diabetes Canada. 2018 National Backgrounder. Available at: http://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx. Accessed August 29, 2018.

10

Diabetes Canada. Heart Disease and Stroke. Available at: https://www.diabetes.ca/diabetes-and-you/complications/heart-disease-stroke. Accessed August 26,2018.

11

Public Health Agency of Canada. (2011). Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, Ont.: Public Health Agency of Canada. Retrieved from https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/cdmc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/pdf/facts-figures-faits-chiffres-eng.pdf. Accessed August 29, 2018. 

12

Institute for Clinical Evaluative Sciences. (2003). Diabetes in Ontario: An ICES Practice Atlas. Retrieved from http://www.ices.on.ca/Publications/Atlases-and-Reports/2003/Diabetes-in-Ontario.aspx. Accessed August 29, 2018.

13

Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J  Educ Health Promot. 2014;3:1.

14

INVOKANA^® Product Monograph, October 15, 2018.

15

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

16

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

17

INVOKANA^® Product Monograph, October 15, 2018.

18

INVOKANA^® Product Monograph, October 15, 2018.

19

INVOKANA^® Product Monograph, October 15, 2018.

20

INVOKANA^® Product Monograph, October 15, 2018.

21

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

22

INVOKANA^® Product Monograph, October 15, 2018.

23

INVOKANA^® Product Monograph, October 15, 2018.

24

INVOKANA^® Product Monograph, October 15, 2018.

25

INVOKANA^® Product Monograph, October 15, 2018.

26

INVOKANA^® Product Monograph. October 15, 2018.

27

Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.